Biotechnology Companies By Pb Ratio

Price To Book
Price To BookEfficiencyMarket RiskExp Return
1PTCT PTC Therapeutics
1.74 K
 0.10 
 4.31 
 0.41 
2ALNY Alnylam Pharmaceuticals
978.7
(0.07)
 2.19 
(0.16)
3RNAC Cartesian Therapeutics
642.47
 0.07 
 6.78 
 0.48 
4RYTM Rhythm Pharmaceuticals
307.53
 0.05 
 3.14 
 0.15 
5PLUR Pluri Inc
306.56
(0.03)
 4.87 
(0.14)
6AGEN Agenus Inc
218.61
(0.15)
 5.55 
(0.83)
7GALT Galectin Therapeutics
207.7
(0.16)
 6.97 
(1.11)
8MRSN Mersana Therapeutics
187.24
(0.01)
 6.56 
(0.05)
9INDV Indivior PLC Ordinary
145.25
 0.11 
 3.86 
 0.44 
10HURA TuHURA Biosciences
133.78
 0.01 
 11.16 
 0.16 
11BBIO BridgeBio Pharma
123.68
 0.06 
 3.57 
 0.21 
12CARM Carisma Therapeutics
114.1
(0.25)
 4.90 
(1.24)
13OCEA Ocean Biomedical
100.67
(0.11)
 4.99 
(0.57)
14ESPR Esperion Therapeutics
98.42
 0.10 
 6.36 
 0.64 
15PROK ProKidney Corp
91.32
(0.05)
 6.58 
(0.34)
16TVTX Travere Therapeutics
76.1
 0.08 
 3.71 
 0.28 
17CHRS Coherus BioSciences
73.19
 0.11 
 7.37 
 0.80 
18EVAX Evaxion Biotech AS
72.85
(0.29)
 5.62 
(1.62)
19APTO Aptose Biosciences
67.84
(0.04)
 10.01 
(0.43)
20BCLI Brainstorm Cell Therapeutics
65.82
(0.06)
 7.46 
(0.45)
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities. Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.